Gene Editing and Clinical Research · uae
Can a Single Infusion Lower Blood Lipids Long Term? Mammoth and M42 Plan a Gene-Editing Trial in the UAE
MB-111 will use lipid nanoparticles to deliver a CRISPR system into liver cells in an attempt to switch off the APOC3 gene to treat persistent chylomicronemia. The collaboration is moving toward clinical evaluation, but no human efficacy results or news of the first participant being dosed have been announced.
For patients with severely elevated triglycerides over the long term, the disease burden extends beyond numbers on a lab report and may include recurrent, life-threatening pancreatitis. Whether a single infusion can deliver sustained improvements in blood lipids is the question Mammoth Biosciences and IROS, the clinical research organization within healthcare group M42, are preparing to test in the United Arab Emirates.
On October 28, the two parties announced plans to conduct a clinical trial of the investigational therapy MB-111 in adults with persistent chylomicronemia. According to M42’s announcement and reporting by the Emirates News Agency WAM, the study will evaluate the safety of a single intravenous infusion and its potential efficacy in sustaining triglyceride reductions. The announcement did not disclose the trial phase, enrollment size, doses, or follow-up period, nor did it announce that the first participant had received treatment.
MB-111 is designed to use lipid nanoparticles to encapsulate and deliver Mammoth’s ultracompact CRISPR gene-editing system, CasPhi, into liver cells, then switch off the APOC3 gene, which is involved in triglyceride regulation. By reducing production of the associated protein, the development team hopes to make the effects of a single dose last; this durability remains a therapeutic goal that has yet to be verified.
Persistent chylomicronemia, the condition targeted by the trial, encompasses different underlying causes. Some patients have familial chylomicronemia syndrome, in which genetic variants make it difficult for the body to clear triglyceride-rich lipoprotein particles; in others, genetic and non-genetic factors act together. According to the announcement, some patients continue to have elevated blood lipids despite conventional treatment, and their lives often involve strict dietary restrictions, ongoing medication, and repeated hospitalizations.
The trial plans build on a collaboration agreement signed by the Department of Health – Abu Dhabi, M42, and Mammoth in June 2026, with IROS providing clinical research capabilities and the Department of Health – Abu Dhabi responsible for regulatory oversight. M42 describes it as the UAE’s first clinical trial of a gene-editing therapy delivered using lipid nanoparticles. Aletihad also published the same news, but its coverage was republished from WAM and did not provide a separate set of clinical evidence.
The progress that can currently be confirmed is that the collaboration has identified a specific therapeutic candidate, target patient population, and direction for clinical evaluation; there are no human efficacy results yet. How much MB-111 can lower triglycerides, how long the effects can last, and whether its safety is sufficient to support long-term use all remain questions for the trial to answer. Whether improvements in blood lipids can further reduce pancreatitis and the burden of hospitalization also cannot be inferred from the mechanism of action alone.